Bellevue Group AG Has $20.75 Million Holdings in Privia Health Group, Inc. (NASDAQ:PRVA)

Bellevue Group AG increased its position in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 0.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,059,171 shares of the company’s stock after acquiring an additional 7,475 shares during the quarter. Bellevue Group AG’s holdings in Privia Health Group were worth $20,749,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in PRVA. Norges Bank acquired a new stake in shares of Privia Health Group during the fourth quarter valued at approximately $27,959,000. Riverbridge Partners LLC grew its position in Privia Health Group by 17.5% during the first quarter. Riverbridge Partners LLC now owns 5,399,662 shares of the company’s stock valued at $105,779,000 after purchasing an additional 804,304 shares in the last quarter. Vanguard Group Inc. grew its position in Privia Health Group by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 11,278,334 shares of the company’s stock valued at $259,740,000 after purchasing an additional 274,345 shares in the last quarter. Sei Investments Co. grew its position in Privia Health Group by 50.7% during the first quarter. Sei Investments Co. now owns 457,880 shares of the company’s stock valued at $8,970,000 after purchasing an additional 154,044 shares in the last quarter. Finally, BlackBarn Capital Partners LP purchased a new position in Privia Health Group during the fourth quarter valued at approximately $3,109,000. Institutional investors and hedge funds own 94.48% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on PRVA. Truist Financial lowered their price objective on shares of Privia Health Group from $28.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, May 15th. Canaccord Genuity Group lowered their price objective on shares of Privia Health Group from $37.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Evercore ISI lowered their price objective on shares of Privia Health Group from $23.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 9th. Robert W. Baird started coverage on shares of Privia Health Group in a research report on Thursday, May 30th. They issued an “outperform” rating and a $23.00 target price for the company. Finally, Barclays decreased their target price on shares of Privia Health Group from $22.00 to $19.00 and set an “equal weight” rating for the company in a research report on Monday, May 20th. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $24.54.

Insider Transactions at Privia Health Group

In related news, EVP Thomas Bartrum sold 1,506 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $17.88, for a total transaction of $26,927.28. Following the completion of the transaction, the executive vice president now directly owns 102,356 shares in the company, valued at approximately $1,830,125.28. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Adam Boehler bought 277,565 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was purchased at an average cost of $16.17 per share, for a total transaction of $4,488,226.05. Following the purchase, the director now directly owns 5,488,701 shares in the company, valued at $88,752,295.17. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, EVP Thomas Bartrum sold 1,506 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $17.88, for a total transaction of $26,927.28. Following the transaction, the executive vice president now owns 102,356 shares of the company’s stock, valued at $1,830,125.28. The disclosure for this sale can be found here. Over the last three months, insiders bought 293,235 shares of company stock worth $4,745,481 and sold 45,457 shares worth $827,810. 14.20% of the stock is owned by corporate insiders.

Privia Health Group Stock Performance

Shares of Privia Health Group stock traded up $0.47 on Friday, reaching $20.46. The stock had a trading volume of 423,617 shares, compared to its average volume of 693,804. The business’s 50-day moving average price is $17.55 and its two-hundred day moving average price is $19.09. Privia Health Group, Inc. has a fifty-two week low of $15.92 and a fifty-two week high of $28.10. The stock has a market cap of $2.44 billion, a P/E ratio of 136.40, a price-to-earnings-growth ratio of 3.21 and a beta of 0.78.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings data on Thursday, May 9th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.03). Privia Health Group had a return on equity of 3.13% and a net margin of 1.11%. The firm had revenue of $415.24 million during the quarter, compared to analyst estimates of $435.07 million. As a group, equities analysts forecast that Privia Health Group, Inc. will post 0.2 earnings per share for the current fiscal year.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.